Tech Company Financing Transactions
Quarry Thera Funding Round
Canaan Partners, F-Prime Capital and Lilly Ventures participated in a $32 million Series A funding round for Quarry Thera. This VC investment round was announced by the company on 11/26/2025.
Transaction Overview
Company Name
Announced On
11/26/2025
Transaction Type
Venture Equity
Amount
$32,000,000
Round
Series A
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
286 Livingston Street
New Haven, CT 06511
USA
New Haven, CT 06511
USA
Phone
Undisclosed
Email Address
Not Recorded
Overview
Quarry Thera - a Biotech with a differentiated pipeline and an unprecedented platform. Quarry Thera is advancing the next generation of proximity-induced therapeutics based on molecular glues. Molecular glues have emerged as a powerful new modality in drug development and combine proprietary DNA-encoded libraries, structurally enabled drug design, and sophisticated medicinal chemistry to address challenges with currently available therapeutic options, including sub-optimal efficacy, narrow therapeutic windows, limited cellular permeability, and selectivity challenges associated with targeting undruggable proteins.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Scientific Officer
Jeanne Magram
Founder
Craig Crews
Founder
Mikael Dolsten
Browse more venture capital transactions:
Prev: 11/26/2025: LabelBlind venture capital transaction
Next: 11/26/2025: Codenotary venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record every notable VC transaction. All VC database entries reported here are sourced from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs